Selling into healthcare or defense can add a second evaluation track to an otherwise strong B2B opportunity. The buyer is not only asking whether the product works, whether the price fits, or whether the supplier can deliver. It may also need to know what data the supplier will touch, which systems it can access, what contractual obligations flow down, and whether the supplier can produce evidence that its controls match those obligations.
The mistake is assuming that every healthcare buyer asks for “HIPAA compliance” or every defense buyer asks for the same DFARS, CMMC, and ITAR evidence. Applicability depends on the relationship.
A software vendor that never accesses protected health information is in a different position from a business associate that stores electronic PHI. A company selling ordinary commercial products to a defense customer is in a different position from a subcontractor that will process Controlled Unclassified Information or ITAR-controlled technical data.
Start With the Data and the Contract, Not the Acronym
Before the sales team promises compliance with a named framework, establish what the proposed relationship actually requires. Ask four questions:
- What information will the supplier create, receive, maintain, transmit, or access?
- Which systems or environments will the supplier connect to?
- What laws, regulations, contract clauses, or customer policies apply to that information or access?
- What evidence will the buyer expect before it approves the supplier?
This is where a security review becomes part of the buying process. The review is not simply a technical hurdle. It can determine whether procurement, legal, information security, privacy, or a government-contracting team is willing to approve the relationship.
Sales should therefore avoid broad statements such as “we are HIPAA compliant,” “we meet DFARS,” or “we are ITAR compliant” until the responsible legal, compliance, security, or contracting owner has confirmed what that statement means for the proposed scope. A confident answer that is too broad can create more commercial risk than a precise answer with a clearly defined boundary.
Healthcare Buyers First Need to Know Whether HIPAA Applies to the Relationship
HIPAA does not automatically apply to every company that sells into healthcare. The Privacy and Security Rules apply to covered entities and, in relevant circumstances, their business associates. A vendor may become a business associate when it creates, receives, maintains, or transmits protected health information on behalf of a covered entity or another business associate.
That distinction matters for technology sellers. HHS specifically notes that merely selling or providing software to a covered entity does not by itself create a business-associate relationship if the vendor does not have access to the covered entity's PHI.
If the proposed service does involve PHI, expect the buyer to ask questions such as:
- Will you sign a Business Associate Agreement?
- Where will PHI and electronic PHI be stored or processed?
- Which employees and subcontractors can access it?
- How do you control and review access?
- How do you assess risks and vulnerabilities affecting ePHI?
- How do you detect, respond to, and report security incidents?
- What happens to the data when the relationship ends?
The HIPAA Security Rule requires appropriate administrative, physical, and technical safeguards for electronic PHI. It also requires risk analysis and risk management; those activities should not be reduced to a one-time questionnaire completed for a prospective customer.
Where the vendor is a business associate, the BAA becomes commercially important because it defines permitted uses and disclosures of PHI and establishes required safeguards and reporting obligations. Subcontractors that handle PHI on behalf of a business associate can create further contractual obligations.
Do Not Sell a Proposed HIPAA Rule as Though It Is Already Law
Healthcare security requirements are evolving, which creates another sales risk: treating a proposal as an effective requirement.
HHS proposed major changes to the HIPAA Security Rule in late 2024. As of November 2026, HHS still identifies that initiative as a Notice of Proposed Rulemaking rather than a final replacement for the current Security Rule. Sellers should monitor the proposal and prepare for likely direction of travel, but customer-facing claims should distinguish the rules in force from controls a buyer may request contractually or adopt as a best practice.
That distinction matters because sophisticated healthcare buyers can set security expectations that go beyond the regulatory minimum. They may ask for stronger authentication, documented recovery testing, penetration-test information, security questionnaires, cyber insurance, SOC reports, or other assurance material. Those can be legitimate buyer requirements without being universal HIPAA requirements.
One particularly important example is certification language. HHS states that business associates cannot simply self-certify or obtain a third-party certificate that makes them “HIPAA certified” in the same way an organization might hold a formal certification under another scheme. A vendor should describe the controls and assurance it actually has rather than relying on an ambiguous badge.
FDA Requirements Apply to Particular Healthcare Products, Not Every Healthcare Sale
The original draft listed FDA regulations alongside HIPAA, but the distinction needs to be sharper. FDA requirements become relevant when the product or activity falls within FDA's regulatory authority, such as certain medical devices, drugs, biologics, or related regulated activities. They are not a generic compliance requirement for every vendor selling to a hospital, clinic, or health plan.
For vendors of connected or software-enabled medical devices, cybersecurity can become part of product regulation as well as enterprise security. FDA's current medical-device cybersecurity guidance, issued in February 2026, addresses cybersecurity design, quality-system considerations, and documentation for devices with cybersecurity risk.
A seller should therefore identify which regulatory role the product occupies before telling a healthcare buyer which standards it meets. A cloud scheduling platform, an outsourced billing service, and a connected diagnostic device can all be sold into healthcare while facing very different compliance questions.
Defense Buyers Will Ask What Information the Contract Puts in Your Environment
Defense compliance is similarly contract- and information-driven. The important distinction is often whether the supplier's systems will process, store, or transmit Federal Contract Information (FCI), Controlled Unclassified Information (CUI), or covered defense information.
DFARS clause 252.204-7012 requires safeguarding of covered defense information on covered contractor information systems and imposes cyber-incident reporting obligations. Where the clause applies, it also ties safeguarding to NIST SP 800-171 requirements specified for the solicitation and includes flow-down obligations for relevant subcontractors.
A defense buyer or prime contractor may therefore ask:
- Will your systems receive FCI, CUI, or covered defense information?
- Which systems are inside the security boundary?
- Do you have a current system security plan?
- What NIST SP 800-171 assessment information is current?
- What remediation items remain open?
- How will incidents be reported and evidence preserved?
- Which subcontractors will receive the same information?
- What cloud services will store or process covered information?
If an external cloud provider will store, process, or transmit covered defense information under DFARS 252.204-7012, the clause includes specific cloud-security expectations, including security requirements equivalent to the FedRAMP Moderate baseline and associated incident-handling obligations.
Sellers should confirm the exact contractual requirement rather than assuming that a familiar commercial cloud configuration is automatically sufficient.
CMMC Is Now Part of the Contracting Conversation, but the Rollout Is Still Moving
CMMC has moved from a future concept into the DFARS contracting framework. DFARS 252.204-7021 provides for required CMMC status at Level 1, Level 2, or Level 3, depending on the solicitation and the information systems used in contract performance.
The current program distinguishes between basic safeguarding of FCI at Level 1 and stronger protection of CUI at Levels 2 and 3. Depending on the solicitation, Level 2 can involve either a self-assessment or a C3PAO assessment, while Level 3 involves a government assessment after achieving Level 2 status.
However, sellers should not rely on an old rollout calendar. A July 13, 2026 CMMC program update suspended the Phase II requirements that had been scheduled to begin on November 10, 2026, while leaving Phase I self-assessment requirements in place. The practical sales lesson is to check the current solicitation, contract language, and program guidance rather than assuming that a generic CMMC timeline answers the buyer's question.
Where CMMC applies, the buyer may ask for a current CMMC status or UID, current self-assessment information in SPRS, annual affirmations, or evidence that subcontractors meet the level appropriate to the information being flowed down.
CMMC should therefore be treated as a contract-readiness question, not simply a marketing credential.
ITAR Is an Export-Control Issue, Not a General Defense Cybersecurity Standard
ITAR is frequently mentioned alongside defense cybersecurity requirements, but it regulates a different problem. The International Traffic in Arms Regulations control defense articles, defense services, and technical data associated with items on the U.S. Munitions List.
The Directorate of Defense Trade Controls states that persons engaged in certain manufacturing, exporting, temporarily importing, defense-service, or brokering activities must register as required by the ITAR. Registration itself does not grant export rights or privileges.
That means a company does not become subject to every ITAR requirement simply because its customer works in defense. Applicability depends on what the company is doing and whether controlled articles, services, or technical data are involved.
If ITAR-controlled technical data enters the proposed workflow, buyers may ask who can access the information, where it can be stored, whether foreign persons may receive it, how cloud access is controlled, and what export authorization applies. DDTC guidance makes clear that enabling a foreign person to access unencrypted controlled technical data can constitute a controlled release requiring authorization.
Sales teams should route those questions to export-control specialists rather than improvising an answer from general cybersecurity documentation.
What Healthcare and Defense Buyers Are Really Trying to Establish
Although the legal regimes differ, the procurement questions often converge around a smaller set of business risks. The buyer wants to understand what the supplier will touch, how that access is controlled, how failure will be detected, and whether the supplier can prove what it says.
| Buyer concern | Healthcare example | Defense example | Useful seller evidence |
|---|---|---|---|
| Data scope | Will the service create, receive, maintain, or transmit PHI or ePHI? | Will the system process, store, or transmit FCI, CUI, covered defense information, or controlled technical data? | Data-flow diagrams, architecture, system boundaries, data classification |
| Access | Who can reach PHI, and how are access rights approved and reviewed? | Who can access contract information or controlled data, including subcontractors and foreign persons? | Access-control policy, MFA evidence, privileged-access process, access reviews |
| Security operations | How are ePHI risks assessed, monitored, and addressed? | How are NIST/DFARS controls operated, monitored, and evidenced? | Risk assessments, monitoring records, vulnerability management, incident procedures |
| Third parties | Which subcontractors handle PHI, and are appropriate BAAs in place? | Which subcontractors receive FCI/CUI, and what requirements flow down? | Vendor inventory, contracts, assurance reports, flow-down records |
| Incident handling | How will incidents and potential breaches involving PHI be escalated and reported? | Can the supplier meet required cyber-incident reporting and evidence-preservation obligations? | Incident-response plan, notification workflow, exercise records |
| Assurance | Can the supplier support its HIPAA-related claims with current evidence? | Can the supplier substantiate NIST, SPRS, CMMC, or export-control statements? | Current assessments, reports, policies, test results, contractual documentation |
Evidence Is More Persuasive Than a Long Compliance Claim
Regulated buyers are often less interested in hearing that a supplier “takes compliance seriously” than in seeing how a control actually works.
A prepared seller should know which evidence can be provided safely and who can approve its release.
Depending on the opportunity, that may include:
- Security and privacy policies
- Architecture and data-flow diagrams
- Risk-assessment summaries
- SOC 2 or other independent assurance reports, where relevant
- Penetration-test or vulnerability-management summaries
- Business Associate Agreement language
- Incident-response and breach-notification procedures
- NIST SP 800-171 assessment information or CMMC status
- System Security Plan information
- Export-control procedures and DDTC registration information where genuinely applicable
- Cyber insurance evidence when requested
Do not send every document automatically. Some material can expose sensitive architecture, security findings, contract information, or controlled data. Use an NDA or controlled review process where appropriate and provide the level of evidence the buyer actually needs.
Prepare Sales to Answer the Scope Question Without Answering the Legal Question
Salespeople need enough compliance knowledge to qualify the opportunity and route the buyer's questions, but they should not become the final authority on regulatory applicability.
A useful sales response is specific about the known facts:
“Our standard deployment does not require access to PHI. If your implementation would involve PHI, our security and legal teams will review the data flow and BAA requirements before we commit to the final architecture.”
Or, in defense:
“We need to confirm whether this work will place FCI or CUI in our environment and which DFARS/CMMC clauses are included in the solicitation. Once that is confirmed, we can map the requirement to the systems and evidence in scope.”
Those answers demonstrate competence without making a promise that may later have to be withdrawn.
Security questionnaires should use the same discipline. Answer what is true today, state the relevant scope, and distinguish an implemented control from a planned improvement. If the answer implies a contractual commitment, such as a notification deadline, data-location restriction, recovery target, or audit right, route it to the appropriate owner before it is sent.
Third-Party Support Can Strengthen Readiness Without Transferring Responsibility
Healthcare and defense suppliers often use outside IT, cybersecurity, cloud, and communications providers to operate parts of their environment. That can improve capability, but the existence of a provider does not itself prove compliance.
Organizations evaluating technology services by CSS can see published capabilities spanning managed IT, security monitoring, access controls, compliance reporting, HIPAA support, and CMMC-oriented services. The relevant sales question is which of those services are actually in scope for the seller's environment and which evidence the seller can produce when a buyer asks.
The same principle applies to communications infrastructure. If the proposed service depends on voice, data, connectivity, network integration, mobile services, or secure communications, teams working with Shabella Communications's team or another provider should know which parts of the buyer-facing requirement depend on that provider and where responsibility remains with the seller.
Do not copy a provider's entire service catalog into a customer questionnaire. A provider may offer controls the seller has not purchased, may operate only part of the environment, or may retain evidence that the seller has not arranged to receive.
Supplier Access Is a Separate Decision From Supplier Approval
A buyer may conclude that the company is an acceptable supplier and still restrict what the supplier can access. That is especially important when the relationship involves PHI, CUI, privileged administration, clinical systems, defense technical data, or other sensitive assets.
Before implementation, clarify the supplier access required to deliver the work. A vendor that only needs an API connection to one dataset should not automatically receive broad network access. A support provider that needs temporary administrative rights should not necessarily retain those privileges permanently.
The access decision should answer:
- What task requires the access?
- Which systems and data become reachable?
- Which supplier personnel or service accounts will use it?
- What level of privilege is required?
- How will activity be logged and reviewed?
- How will access be changed or removed when the work changes?
For regulated buyers, the implementation design can therefore become part of the compliance discussion before the commercial contract is finally approved.
Build a Compliance Readiness Pack Before the Buyer Asks
The fastest way to create sales friction is to discover during procurement that every answer lives with a different employee and every piece of evidence has to be assembled from scratch.
A reusable readiness pack can reduce that problem. It does not need to contain every confidential document. It should identify what exists, who owns it, and under what conditions it can be shared.
A practical pack can include:
- A short description of the service and data flows
- A current security overview
- A list of applicable assurance reports and certifications
- Standard answers for common access, encryption, backup, and incident questions
- A BAA process for healthcare opportunities where applicable
- Current defense-contract assessment or CMMC information where applicable
- Subprocessor or subcontractor information
- Standard contractual security language
- Named internal owners for privacy, security, legal, export control, and government-contract questions
Version control matters. A six-month-old questionnaire can become dangerous if the architecture, vendors, policies, CMMC status, or customer commitments have changed since it was approved.
Treat Compliance Questions as Commercial Intelligence
Buyer questions reveal more than regulatory concern. They show how the organization evaluates supplier risk and who else is involved in the purchasing decision.
A healthcare buyer asking detailed BAA, data-flow, and incident-notification questions may be bringing privacy, legal, or information-security stakeholders into the opportunity. A defense prime asking about CUI boundaries, SPRS, CMMC, subcontractors, and export controls is signaling that contract eligibility and supply-chain risk are part of the evaluation.
Sales should record those constraints. They can affect implementation design, pricing, contract terms, deployment timelines, and even whether the opportunity is realistically winnable.
The aim is not to treat compliance as a sales trick. It is to recognize that in regulated markets, supplier readiness is part of the product the buyer is evaluating.
Compliance Claims Should Be Narrow Enough to Defend
Healthcare and defense buyers do not need a supplier to recite every regulation in the sector. They need the supplier to understand the obligations created by the proposed relationship and to be able to support its answers.
That means distinguishing HIPAA applicability from general healthcare security, FDA regulation from ordinary healthcare procurement, DFARS from CMMC, and ITAR export controls from broader defense cybersecurity. It also means knowing where the seller's own controls stop and a cloud provider, subcontractor, managed-service provider, or customer responsibility begins.
The strongest compliance position is usually the most precise one: this is the data we will handle, these are the systems in scope, these are the requirements that apply, these are the controls we operate, and this is the evidence we can provide.
That level of clarity reduces late-stage surprises and helps regulated buyers make a decision without forcing sales to promise more than the organization can actually deliver.
Before the Security Questionnaire: Compliance Questions Sellers Should Be Ready to Answer
Do we need to sign a BAA just because the customer is a healthcare organization?
No. A healthcare customer does not automatically make every vendor a HIPAA business associate. The key question is whether the vendor will create, receive, maintain, or transmit PHI on behalf of the covered entity or another business associate.
If the proposed service never gives the vendor access to PHI, a BAA may not be required. Confirm the actual data flow and role rather than deciding the customer's industry alone.
Is a SOC 2 report enough to prove HIPAA compliance?
No. A SOC 2 report can provide useful independent assurance about controls, but it is not a HIPAA certification and does not by itself determine whether an organization has met every HIPAA obligation applicable to its role. Healthcare buyers may use SOC 2 as one piece of due diligence alongside a BAA, security questionnaire, risk information, policies, and other evidence.
Does every company selling to the Department of Defense need CMMC?
No. The requirement depends on the solicitation, contract, information being handled, and systems used in performance. During the phased implementation period, CMMC requirements are included in specified contracts rather than automatically applied to every defense sale.
Sellers should check the actual solicitation and current DFARS/CMMC guidance instead of assuming the customer's industry determines the requirement.
What does the 2026 suspension of CMMC Phase II mean for sellers?
It means sellers should not rely on an outdated rollout schedule. The July 2026 program update suspended Phase II requirements that had been scheduled to begin on November 10, 2026, while keeping Phase I self-assessment requirements in place. Existing DFARS safeguarding and NIST assessment obligations also remain relevant where their clauses apply.
Check the current solicitation and program guidance for the specific opportunity.
Does ITAR mean all data must stay in the United States and only U.S. citizens can touch it?
Not as a universal rule. ITAR controls particular defense articles, defense services, and technical data, and the exact authorization depends on the activity and recipients involved.
Foreign-person access to controlled technical data can create an export-control issue, but ITAR also contains specific rules and exceptions addressing encrypted data and authorized access. Export-control counsel or a qualified specialist should determine the correct treatment for the actual technical data and workflow.
How much evidence should we give a prospect before the contract is signed?
Enough to support the buyer's reasonable due diligence without unnecessarily exposing sensitive security or controlled information.
A high-level security overview, current assurance report, policy summary, or controlled response to a questionnaire may be appropriate early in the process, while detailed architecture, penetration-test findings, system security plans, or export-controlled information may require an NDA, restricted review, or a later stage of diligence. Define who can approve disclosure before sales starts sending documents.